Tanya Weinstock is a Respiratory physician affiliated with Vertex Pharmaceuticals. OpenAlex indexes 31 publications with 1,275 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
133 Brookline Ave
Pulmonary Dept
Boston, MA 022153904
Telephone
617-421-1380Registry record last updated 25 Feb 2013.
Clinical trials
- Effects of Treatment of Sleep Apnea on Metabolic Syndrome
Sponsor: Brigham and Women's Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Corticosteroid59%Breo Ellipta45%Trelegy Ellipta37%Symbicort18%Part D<11 patientsbeta2-Adrenergic Agonist17.5%Ventolin Hfa60%Albuterol Sulfate Hfa40%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare <i>CFTR</i> variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study
American Journal of Respiratory and Critical Care Medicine
2026 - Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial
American Journal of Respiratory and Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David Waltz, MD
Vertex Pharmaceuticals
Suzan Imren, MD
Vertex Pharmaceuticals
Peter Michelson, MD
Vertex Pharmaceuticals
Laval Chan
Vertex Pharmaceuticals
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”